Ganciclovir
Common brands: Zirgan, Prograf, Envarsus Xr, Cellcept, Tacrolimus
Top reporter: Bausch & Lomb Incorporated
Cytomegalovirus Nucleoside Analog DNA Polymerase Inhibitor [EPC]Nucleoside Analog Antiviral [EPC]Corticosteroid [EPC]Calcineurin Inhibitor Immunosuppressant [EPC]Azole Antifungal [EPC]
10,024
Total Reports
5,641
Serious Reports
3,081
Death Reports
30
Reported Reactions
Death Report Ratio: High (30.74%)
Patient Demographics
Reported Adverse Reactions (30)
Side effects reported in FDA adverse event reports for Ganciclovir.
| # | Reaction | Reports | % of Total |
|---|---|---|---|
| 1 | OFF LABEL USE | 1,602 | |
| 2 | DRUG INEFFECTIVE | 1,417 | |
| 3 | CYTOMEGALOVIRUS INFECTION | 1,188 | |
| 4 | DRUG RESISTANCE | 665 | |
| 5 | PYREXIA | 595 | |
| 6 | PRODUCT USE IN UNAPPROVED INDICATION | 550 | |
| 7 | NEUTROPENIA | 512 | |
| 8 | PANCYTOPENIA | 510 | |
| 9 | DIARRHOEA | 436 | |
| 10 | CYTOMEGALOVIRUS VIRAEMIA | 422 | |
| 11 | PNEUMONIA | 418 | |
| 12 | SEPSIS | 409 | |
| 13 | MULTIPLE ORGAN DYSFUNCTION SYNDROME | 393 | |
| 14 | RESPIRATORY FAILURE | 384 | |
| 15 | CYTOMEGALOVIRUS INFECTION REACTIVATION | 366 | |
| 16 | THROMBOCYTOPENIA | 355 | |
| 17 | LEUKOPENIA | 345 | |
| 18 | CONDITION AGGRAVATED | 324 | |
| 19 | RENAL IMPAIRMENT | 320 | |
| 20 | ACUTE KIDNEY INJURY | 310 | |
| 21 | PRODUCT USE ISSUE | 307 | |
| 22 | PATHOGEN RESISTANCE | 295 | |
| 23 | RENAL FAILURE | 284 | |
| 24 | ANAEMIA | 280 | |
| 25 | POST TRANSPLANT LYMPHOPROLIFERATIVE DISORDER | 256 | |
| 26 | SEPTIC SHOCK | 255 | |
| 27 | EPSTEIN-BARR VIRUS INFECTION | 252 | |
| 28 | NEPHROPATHY TOXIC | 240 | |
| 29 | TRANSPLANT REJECTION | 222 | |
| 30 | GRAFT VERSUS HOST DISEASE | 219 |
Important Disclaimer
FDA adverse event reports are submitted voluntarily and do not prove causation. A reported reaction does not mean the drug caused it. Drugs with more users naturally have more reports. Always consult your doctor or pharmacist before making medication decisions.